Inserm U590, Laboratoire de Cytologie Analytique, Université Lyon 1, 69008 Lyon, France.
BMC Cancer. 2010 Apr 12;10:135. doi: 10.1186/1471-2407-10-135.
Microtubules are considered major therapeutic targets in patients with breast cancer. In spite of their essential role in biological functions including cell motility, cell division and intracellular transport, microtubules have not yet been considered as critical actors influencing tumor cell aggressivity. To evaluate the impact of microtubule mass and dynamics on the phenotype and sensitivity of breast cancer cells, we have targeted tubulin binding cofactor C (TBCC), a crucial protein for the proper folding of alpha and beta tubulins into polymerization-competent tubulin heterodimers.
We developed variants of human breast cancer cells with increased content of TBCC. Analysis of proliferation, cell cycle distribution and mitotic durations were assayed to investigate the influence of TBCC on the cell phenotype. In vivo growth of tumors was monitored in mice xenografted with breast cancer cells. The microtubule dynamics and the different fractions of tubulins were studied by time-lapse microscopy and lysate fractionation, respectively. In vitro sensitivity to antimicrotubule agents was studied by flow cytometry. In vivo chemosensitivity was assayed by treatment of mice implanted with tumor cells.
TBCC overexpression influenced tubulin fraction distribution, with higher content of nonpolymerizable tubulins and lower content of polymerizable dimers and microtubules. Microtubule dynamicity was reduced in cells overexpressing TBCC. Cell cycle distribution was altered in cells containing larger amounts of TBCC with higher percentage of cells in G2-M phase and lower percentage in S-phase, along with slower passage into mitosis. While increased content of TBCC had little effect on cell proliferation in vitro, we observed a significant delay in tumor growth with respect to controls when TBCC overexpressing cells were implanted as xenografts in vivo. TBCC overexpressing variants displayed enhanced sensitivity to antimicrotubule agents both in vitro and in xenografts.
These results underline the essential role of fine tuned regulation of tubulin content in tumor cells and the major impact of dysregulation of tubulin dimer content on tumor cell phenotype and response to chemotherapy. A better understanding of how the microtubule cytoskeleton is dysregulated in cancer cells would greatly contribute to a better understanding of tumor cell biology and characterisation of resistant phenotypes.
微管被认为是乳腺癌患者的主要治疗靶点。尽管它们在细胞运动、细胞分裂和细胞内运输等生物学功能中起着至关重要的作用,但微管尚未被认为是影响肿瘤细胞侵袭性的关键因素。为了评估微管质量和动力学对乳腺癌细胞表型和敏感性的影响,我们针对微管结合辅助因子 C(TBCC)进行了研究,TBCC 是一种对 α 和 β 微管蛋白正确折叠成有聚合能力的微管异二聚体至关重要的蛋白质。
我们开发了人乳腺癌细胞中 TBCC 含量增加的变体。通过分析增殖、细胞周期分布和有丝分裂持续时间来研究 TBCC 对细胞表型的影响。通过将乳腺癌细胞异种移植到小鼠中监测肿瘤的体内生长。通过延时显微镜和溶酶体分级分离分别研究微管动力学和不同微管蛋白的分数。通过流式细胞术研究体外对微管抑制剂的敏感性。通过用载有肿瘤细胞的小鼠进行治疗来检测体内化疗敏感性。
TBCC 过表达影响微管蛋白分数分布,具有更高含量的不可聚合微管蛋白和更低含量的可聚合二聚体和微管。TBCC 过表达的细胞中微管动力学降低。含有更多 TBCC 的细胞的细胞周期分布发生改变,G2-M 期的细胞比例更高,S 期的细胞比例更低,进入有丝分裂的速度也更慢。虽然 TBCC 含量的增加对体外细胞增殖影响不大,但当 TBCC 过表达细胞作为异种移植物植入体内时,我们观察到肿瘤生长明显延迟。TBCC 过表达变体在体外和异种移植物中均显示出对微管抑制剂的敏感性增强。
这些结果强调了微调肿瘤细胞中微管蛋白含量的重要性,以及微管二聚体含量失调对肿瘤细胞表型和化疗反应的重大影响。更好地了解癌细胞中微管细胞骨架是如何失调的,将极大地有助于更好地理解肿瘤细胞生物学和耐药表型的特征。